In this study, no treatment-induced immunosuppression as assessed by DTH, CD4, CD8, immunoglobulin, and complement levels was observed, an important consideration, given the immunosuppression frequently observed in glioblastoma patients, both due to their disease and treatment27. This evidence concerns the gene CD4 and glioblastoma.